Lighthouse Pharma Direct Investment Page
Lighthouse Pharma leverages translational insights and extensive clinical experience to better understand and treat dementia and other disorders. The team has a decade of data informing their strategy, including patient responder analyses, rigorous dose modeling, and clinical execution.
Portfolio Company | In the News
Lighthouse Pharmaceuticals Announces Progression of LHP588 Clinical Development Program in Alzheimer's Disease
May 10, 2023
Lighthouse announces FDA approval to proceed with Phase 2 SPRING Trial of LHP588, a next-generation treatment in development for Alzheimer's disease
November 16, 2023
Company Updates
Videos
Company update and overview from CEO Casey Lynch | February 6, 2024
Quarterly Reports
The highlights of Q3 2024 updates as provided by the company. Please note all updates provided are confidential and not for distribution.
Leadership Team
